Unione Europea - italiano - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - immunosoppressori - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) è indicato per il trattamento di pazienti adulti con mieloma multiplo precedentemente non trattato e che non sono idonei per il trapianto. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - lenalidomidum - capsule rigide - lenalidomidum 2.5 mg, lactosum 73.5 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.2 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), e 132, drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - lenalidomidum - capsule rigide - lenalidomidum 5 mg, lactosum 147 mg, cellulosum microcristallinum, carmellosum natricum solo tenuti insieme corrisp. sodio 0,4 mg, magnesio stearas, kapselhülle: gelatina, e-171, drucktinte: lacca, propylenglycolum, e 172 (nero), kalii hydroxidum, per una piccola scatola. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - lenalidomidum - capsule rigide - lenalidomidum 7.5 mg, lactosum 144.5 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.4 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - lenalidomidum - capsule rigide - lenalidomidum 10 mg, lactosum 294 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.8 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 132, e 172 (flavum), drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - lenalidomidum - capsule rigide - lenalidomidum 15 mg, lactosum 289 mg, cellulosum microcristallinum, carmellosum natricum solo tenuti insieme corrisp. sodio 0,8 mg, magnesio stearas, kapselhülle: gelatina, e-171, e 132, drucktinte: lacca, propylenglycolum, e 172 (nero), kalii hydroxidum, per una piccola scatola. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - lenalidomidum - capsule rigide - lenalidomidum 20 mg, lactosum 244.5 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.8 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 132, e 172 (flavum), drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - lenalidomidum - capsule rigide - lenalidomidum 25 mg, lactosum 200 mg, cellulosum microcristallinum, carmellosum natricum solo tenuti insieme corrisp. sodio 0,8 mg, magnesio stearas, kapselhülle: gelatina, e-171, drucktinte: lacca, propylenglycolum, e 172 (nero), kalii hydroxidum, per una piccola scatola. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - lenalidomidum - capsule rigide - lenalidomidum 2.5 mg, lactosum 20.0 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.204 mg, magnesii stearas, kapselhülle: gelatina, e 132, titanii dioxidum, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - lenalidomidum - capsule rigide - lenalidomidum 5.0 mg, lactosum 40.0 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.408 mg, magnesii stearas, kapselhülle: gelatina, titanii dioxidum, drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika